<DOC>
	<DOC>NCT00647270</DOC>
	<brief_summary>To demonstrate the efficacy of 80 mg adalimumab monthly dosing compared with placebo and demonstrate the non-inferiority of monthly dosing of 80 mg adalimumab compared with dosing of 40 mg adalimumab every other week.</brief_summary>
	<brief_title>Study Comparing 80 mg of Adalimumab With Placebo, and Demonstrating the Non-inferiority of Monthly 80 mg Adalimumab Dosing Compared With 40 mg Adalimumab Every Other Week Dosing</brief_title>
	<detailed_description>The objective of this study is to demonstrate the efficacy of 80 mg adalimumab monthly dosing compared with placebo as measured by ACR20 response criteria following 12 weeks of therapy. The study is also designed to demonstrate the non-inferiority of monthly dosing of 80 mg adalimumab compared with dosing of 40 mg adalimumab eow as measured by ACR20 response criteria at Week 12.</detailed_description>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Subject &gt; 18 years of age Subject has a diagnosis of RA as defined by the 1987revised ACRclassification criteria and has a disease duration for a minimum of three months Subject must meet the following two criteria: a) At least 6 swollen joints out of 66 assessed, or b) At least 6 tender joints out of 68 assessed If a subject is on MTX, the doses must be stable for at least 4 weeks prior to Screening blood draw and follow standard recommendations for MTX treatment Subject is judged to be in generally good health as determined by the principal investigator Subject has previous exposure to any systemic antiTNF therapy (eg, infliximab, etanercept, certolizumab pegol or golimumab) including adalimumab Subject has a history of acute inflammatory joint disease of different origin other than RA Subject has been treated with any investigational biologic agents Subject considered by the investigator, for any reason, to be an unsuitable candidate for the study Female subject who is pregnant or breastfeeding or considering becoming pregnant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
</DOC>